Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


The wide variability in clinical outcomes among patients undergoing anti–PD-1/PD-L1 immunotherapy has increased interest in finding biomarkers that predict response.

Biomarker Combos May Hold Key to Anti-PD-1/PD-L1 Therapy Response

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

A phase I/II study will explore the delta-like protein 3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) with the PD-1 inhibitor nivolumab (Opdivo) alone or in combination with the CTLA-4 inhibitor ipilimumab (Yervoy) for patients with relapsed extensive-stage small cell lung cancer.

Novel Combination Study Planned for SCLC

Where Immuno-Oncology Is Heading

Brentuximab Vedotin in Advanced Lymphoid Malignancies

 Anti-CD20 Antibodies for Advanced Hematologic Malignancies

Obinutuzumab for Indolent Lymphoma

Immunochemotherapy for Lymphoma

Resistance with CAR-T Therapy

Where Does CAR-T Fit in the Context of Transplant?

Recent Trials of CAR-T Therapy

Toxicity Management for CAR-T in Hematologic Malignancies

Obstacles to Using CAR-T Therapy in Hematologic Malignancies

CAR-T Cell Therapy in Hematologic Malignancies

The Potential for Combining Checkpoint Inhibitors

Immunotherapy for Follicular Lymphoma

Immunotherapy in Refractory DLBCL

PD-1 Inhibitors in Hodgkin Lymphoma

Immunotherapy Response Among Hematologic Malignancies

Immuno-Oncology

Immuno-Oncology | Specialty